[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"thoracoscopic-surgery\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:thoracoscopic-surgery":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,51,85,112,156,177],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100624399","tubeless-strategy-for-enhanced-recovery-after-sublobar-resection-100624399",false,"NCT07409129","Tubeless Strategy for Enhanced Recovery After Sublobar Resection","Tubeless Strategy Within an Enhanced Recovery After Surgery (ERAS) Protocol for Thoracoscopic Sublobar Resection: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Age between 18 and 75 years.\n* Scheduled for uniportal or multiportal video-assisted thoracoscopic surgery (VATS) for sublobar resection (wedge or segmentectomy).\n* Presence of peripheral lung nodules ≤ 2 cm in diameter and ≤ 2 cm from the pleura, confirmed by CT scan.\n* Ability to understand and provide written informed consent.\n* American Society of Anesthesiologists (ASA) physical status I-III.\n\nExclusion Criteria:\n\n* Severe pleural adhesions or fibrosis that would preclude non-intubated anesthesia or tubeless approach.\n* Severe cardiopulmonary dysfunction: FEV1 \\\u003C 50% predicted, DLCO \\\u003C 60% predicted, heart failure (NYHA class III-IV), or unstable angina.\n* Pregnancy or lactation (confirmed by urine test if applicable).\n* Inability to tolerate one-lung ventilation due to anatomical or physiological reasons.\n* History of ipsilateral thoracic surgery.\n* Active pulmonary infection, uncontrolled diabetes, or other comorbidities that increase surgical risk.\n* Participation in another interventional trial within 30 days.","ALL","18 Years","75 Years",{"count":20,"type":21},138,"ESTIMATED","INTERVENTIONAL",[24],"NA","This is a prospective, randomized controlled clinical trial conducted at a single center. The study aims to evaluate whether a \"tubeless\" strategy can enhance recovery for patients undergoing minimally invasive thoracoscopic sublobar resection (wedge or segment resection) for small lung nodules.\n\nParticipants will be randomly assigned to one of two groups:\n\n* The experimental group will receive the \"tubeless\" strategy, which includes non-endotracheal intubation anesthesia (using a laryngeal mask) and no routine chest tube drainage after surgery.\n* The control group will receive the traditional strategy, which includes double-lumen endotracheal intubation anesthesia and routine chest tube drainage.\n\nThe main goal is to compare the rate of achieving high-quality fast-track recovery at 24 hours after surgery between the two groups. This study will provide evidence on whether the tubeless approach can help patients recover faster and more comfortably without compromising safety.",[27,28,29,30],"Pulmonary Nodules","Early Stage Lung Cancer (I and II)","Thoracoscopic Surgery","Sublobar Resection",[32,33,34,35,36,37],"Tubeless Surgery","Non-intubated Anesthesia","Enhanced Recovery After Surgery","Sublobar resection","Wedge Resection","Segmentectomy","NOT_YET_RECRUITING","2026-02-06",{"date":41,"type":42},"2026-02-13","ACTUAL",{"date":44,"type":21},"2026-02-01",{"date":46,"type":21},"2026-09-01",{"name":48,"class":49},"The First Affiliated Hospital of Guangzhou Medical University","OTHER",1,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":16,"minAge":59,"maxAge":60,"enrollmentInfo":61,"targetDuration":4,"studyType":22,"phases":63,"briefSummary":65,"conditions":66,"keywords":69,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":50},"100595141","phase-4-effects-of-ciprofol-on-myocardial-injury-after-non-cardiac-surgery-in-video-assisted-thoracoscopic-surgery-100595141","NCT07028593","Effects of Ciprofol on Myocardial Injury After Non-cardiac Surgery in Video-Assisted Thoracoscopic Surgery","Effects of Ciprofol on Myocardial Injury After Non-cardiac Surgery (CP-MINS) in Patients Undergoing Video-Assisted Thoracoscopic Surgery: A Randomized, Double-Blind, Propofol-Controlled, Multicenter Trial","CP-MINS","Inclusion Criteria:\n\n1. Scheduled for elective video-assisted thoracoscopic (VATS)-assisted thoracic surgery (lobectomy, segmentectomy, wedge resection of two or more lung tissues, mediastinal tumor resection) under general anesthesia;\n2. Aged 45 to 80 years (inclusive) at the time of randomization;\n3. Expected postoperative hospital stay of ≥3 days;\n4. Signed a written informed consent to participate in the study.\n\nExclusion Criteria:\n\n1. Patients allergic to propofol, Ciprofol, or analogs of drug excipient components (soybeans, eggs, milk);\n2. Patients with unstable angina;\n3. Patients with congestive heart failure or hemodynamic instability requiring vasopressor agents;\n4. Patients with severe COPD (FEV1 \\\u003C 1 L);\n5. Glomerular filtration rate \\[eGFR\\] \\\u003C 30 mL\u002Fmin\u002F1.73m²;\n6. Patients with severe hepatic dysfunction (ALT or AST elevation exceeding 1.5 times the upper limit of normal);\n7. Male or female patients planning to conceive within the next 3 months;\n8. Pregnant or lactating female patients;","40 Years","80 Years",{"count":62,"type":21},1058,[64],"PHASE4","Myocardial injury after noncardiac surgery (MINS) refers to postoperative elevation of cardiac troponin (cTn) levels caused by underlying ischemic mechanisms (i.e., coronary artery supply-demand imbalance or atherosclerotic thrombosis) without obvious non-ischemic causes (such as pulmonary embolism), with at least one cTn concentration exceeding the 99th percentile of the test reference upper limit, regardless of whether clinical symptoms and ECG changes are present. MINS, including myocardial infarction and ischemic myocardial injury, typically occurs within 30 days after surgery, most commonly within the first 2 postoperative days. It is an independent risk factor for 30-day postoperative mortality and is also closely associated with increased risk of mortality and vascular complications within 2 years . MINS is a common cardiovascular complication after thoracic surgery. Therefore, reducing the incidence of MINS in non-cardiac thoracic surgery to improve patient outcomes is a critical issue in anesthetic management for thoracic surgery.\n\nCiprofol is a Class 1 innovative drug independently developed in China with global intellectual property rights. Currently, Ciprofol has completed Phase III clinical trials in China and the United States; its approved indications in China include sedation or anesthesia for various diagnostic procedures, general anesthesia for surgical operations, and sedation during intensive care unit (ICU) stays. Completed drug clinical trials and published clinical trial data of Ciprofol indicate that it can better maintain circulatory stability and ideal anesthetic depth during anesthesia induction and maintenance, making it a promising intravenous general anesthetic alternative to propofol.\n\nMaintaining hemodynamic stability is an important measure to reduce cardiovascular complications during the perioperative period. Given the good circulatory stability and sedative efficacy of Ciprofol, this study aims to investigate the impact of Ciprofol on MINS in non-cardiac thoracic surgery.",[67,68,29],"Myocardial Injury","Thoracic Diseases",[70,71,72,73,74],"Myocardial Injury after non-cardiac surgery","Ciprofol","propofol","Video-Assisted Thoracoscopic Surgery","lung tumor","RECRUITING","2026-01-26",{"date":78,"type":42},"2026-01-28",{"date":80,"type":42},"2025-07-31",{"date":82,"type":21},"2027-12",{"name":84,"class":49},"Tongji Hospital",{"id":86,"slug":87,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":4,"eligibilityCriteria":91,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":92,"targetDuration":4,"studyType":22,"phases":94,"briefSummary":95,"conditions":96,"keywords":98,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":50},"100620836","clinical-application-of-right-visual-double-lumen-tube-in-thoracoscopic-surgery-for-adult-patients-100620836","NCT07362797","Clinical Application of Right Visual Double Lumen Tube in Thoracoscopic Surgery for Adult Patients","Comparison of Clinical Application of Right Visual Double Lumen Tube and Right Ordinary Double Lumen Tube in Thoracoscopic Surgery for Adult Patients","Inclusion Criteria:\n\n* Age: at least 18 years old, gender is not limited.\n* American Anesthesiologists Association (ASA) Grade I-III;\n* Elective Video-Assisted Thoracoscopic Lobectomy.\n* Informed consent of the patient or family member.\n* People who are willing to accept perioperative visits.\n\nExclusion Criteria:\n\n* Patients with contraindications for right double-lumen tube insertion (such as right bronchial tumor).\n* The patient has known tracheobronchial anatomical abnormalities\n* Patients previously diagnosed or suspected of having airway difficulty.\n* Patients who need rapid sequence induction.\n* Patients requiring emergency surgery\n* Patients who have undergone thoracic surgery, systemic infection or suspected tuberculosis in the past four weeks.",{"count":93,"type":21},500,[24],"This clinical trial aims to understand whether a visual double-lumen intubation tube can improve the first-attempt success rate and reduce complications compared to a standard double-lumen tube. The trial primarily aims to answer the following questions:\n\nDoes a double-lumen tube improve the first-attempt success rate?\n\nDoes a visual double-lumen tube reduce the likelihood of obstruction of the right upper lobe bronchial opening?\n\nDoes a visual double-lumen tube require fewer adjustments during surgery?\n\nDo patients with visual double-lumen tubes experience fewer perioperative complications compared to those with standard double-lumen tubes?\n\nParticipants will:\n\nUse a visual double-lumen tube partially and a standard double-lumen tube partially.\n\nRecord the perioperative status of all patients.",[29,97],"Double Lumen Tube Intubation",[99,100,101,102],"double lumen tube","FOB","thoracoscopic surgery","Visual dual-lumen tube","2026-01-14",{"date":105,"type":42},"2026-01-23",{"date":107,"type":21},"2025-12-30",{"date":109,"type":21},"2026-12-31",{"name":111,"class":49},"Diansan Su",{"id":113,"slug":114,"hasResults":11,"nctId":115,"briefTitle":116,"officialTitle":117,"acronym":4,"eligibilityCriteria":118,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":119,"targetDuration":4,"studyType":22,"phases":121,"briefSummary":122,"conditions":123,"keywords":136,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":50},"100580294","high-resolution-pet-ct-specimen-imaging-for-the-perioperative-visualization-of-resection-margins-100580294","NCT06835426","High-resolution PET-CT Specimen Imaging for the Perioperative Visualization of Resection Margins","High-resolution PET-CT Specimen Imaging for the Perioperative Visualization of Resection Margins: an Exploratory Pilot Study","A. Inclusion Criteria:\n\n* able to understand treatment protocol and informed consent form\n* estimated by the investigator to be compliant for study participation\n\n  1\\. Fulfilling all group-specific inclusion criteria:\n* confirmed breast cancer with an indication to undergo breast conserving surgery\n* confirmed prostate cancer with an indication to undergo resective surgeryprostatectomy;\n* confirmed thyroid lesion with an indication to undergo resective surgery;\n* confirmed parathyroid adenoma with an indication to undergo resective surgery;\n* suspected basal cell carcinoma, squamous cell carcinoma or melanoma with an indication to undergo resective surgery;\n* suspected lesion in genitourinary sites (including bladder cancer, renal pelvis and ureter carcinoma, adrenal cortical carcinoma and renal cell carcinoma) with an indication to undergo resective surgery;\n* suspected lesion in the head \\& neck region with an indication to undergo resective surgery;\n* confirmed primary or secondary hepatobiliary cancer with an indication to undergo resective surgery;\n* patients undergoing biopsy after metabolic active lesions were detected on a PET scan.\n* suspected neuro-endocrine malignancies with an indication to undergo resective surgery.\n* suspected brain tumor with an indication to undergo resective surgery.\n* Suspected malignant and benign gastrointestinal lesions with an indication to undergo resective surgery.\n* suspected malignant thoracovascular lesions with an indication to undergo resective surgery\n\nB. Exclusion Criteria:\n\n* general or local contra-indications for resective surgery;\n* in case of FDG-based PET tracers: a blood glucose level over 200 mg\u002FdL on the day of surgery;\n* pregnancy or lactation;\n* participation in other clinical studies with a radiation exposure of more than 1 mSv in the past year.",{"count":120,"type":21},150,[24],"These are patients in whom a benign or malignant tumor was recorded requiring surgery. During that surgery, the surgeon will cut away the tumor as part of the treatment of the disease. In this process, it is important that the tumor is removed correctly and completely. To verify that the correct tissue was completely removed, the tissue is examined microscopically. However, a microscopic analysis takes a relatively long time and the result is not known until a few days after the surgery is completed. If that microscopic analysis should eventually reveal that the tumor was not completely removed, additional treatment is usually necessary. An assessment of the excised tissue during surgery would allow additional tissue to be excised in the same operation if necessary. Thus, in this way, additional treatments can also be avoided. This could lead to shorter treatment time and less emotional strain for the patient, as well as lower costs. To date, however, there are no effective techniques to do this.\n\nPositronEmissionTomography (PET) imaging can be used to image the tumor that needs to be excised. To do this, a tracer must be administered through the blood before the operation. This tracer is a slightly radioactive substance that can be detected by the PET camera even at low concentrations. This technique is already routinely used in the hospital to detect cancer or inflammatory tissue in the body. During this study, however, it's not the intention to look at the tumor while it is still in the patient's body, but rather after it has been cut out of the patient's body by the surgeon. To do this, the piece of tissue cut away will be scanned using a specially designed PET-CT scanner.\n\nThe overall goal of this study is to gain additional knowledge. More specifically, the investigators wish to determine which medical conditions may benefit from high-resolution PET-CT specimen imaging.",[124,125,126,127,128,129,130,131,132,133,134,135,29],"Breast Carcinoma","Prostate Cancer Surgery","Thyroid Cancer","Parathyroid Adenomas","Skin Cancer","Genitourinary Cancer","Head and Neck Cancer","Hepatobiliary Cancers","Metabolic Abnormality","Neuro Endocrine Tumours","Brain Tumours","Gastro Intestinal Cancer",[137,138,139,140,141,142,143,144,145,146],"resective surgery","perioperative high-resolution PET-CT specimen imaging","breast cancer","Prostate cancer","thyroid cancer","parathyroid cancer","head and neck cancer","neuro-endocrine malignancies","genitourinary malignacies","thoracovascular malignancies","2025-02-14",{"date":149,"type":42},"2025-02-19",{"date":151,"type":42},"2023-08-06",{"date":153,"type":21},"2027-06-30",{"name":155,"class":49},"Algemeen Ziekenhuis Maria Middelares",{"id":157,"slug":158,"hasResults":11,"nctId":159,"briefTitle":160,"officialTitle":160,"acronym":4,"eligibilityCriteria":161,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":162,"targetDuration":4,"studyType":22,"phases":164,"briefSummary":165,"conditions":166,"keywords":4,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":169,"startDateStruct":171,"completionDateStruct":173,"leadSponsor":175,"locationsCount":50},"100576870","investigation-on-the-status-quo-of-hyperalgesia-in-patients-after-thoracoscopic-operation-and-study-on-the-effect-of-intraoperative-intervention-100576870","NCT06790914","Investigation on the Status Quo of Hyperalgesia in Patients After Thoracoscopic Operation and Study on the Effect of Intraoperative Intervention","Inclusion Criteria:\n\n* Patients selected by the same group of surgeons to perform thoracoscopic three-hole radical resection of lung cancer\n* Patients ≥18 years old, able to communicate effectively and cooperate with the completion of clinical trials\n* ASA grade I-III\n* Normal hearing; Patients who have not participated in other trials in the last two months\n\nExclusion Criteria:\n\n* Previous history of thoracic surgery\n* History of chronic pain and any intake of analgesics 48 hours before surgery; ● Have a history of mental illness, or have taken psychiatric drugs or received psychological treatment in the past six months\n* Deformity of the auricle, inability to wear headphones, and failure to cooperate with this study for any reason\n* suffering from concurrent severe organ system diseases and hearing impairment\n* Incomplete data collection",{"count":163,"type":21},90,[24],"To explore the status quo and influencing factors of hyperpain in patients after thoracoscopic surgery, and to explore the effect of earphone sound isolation during combined operation of flurbiprofen axidate and binaural beat music played by earphone during combined operation on the intervention of hyperpain after thoracoscopic surgery.",[29,167],"Hyperalgesia","2025-01-19",{"date":170,"type":42},"2025-01-24",{"date":172,"type":42},"2024-03-17",{"date":174,"type":21},"2025-03-17",{"name":176,"class":49},"Fujian Medical University Union Hospital",{"id":178,"slug":179,"hasResults":11,"nctId":180,"briefTitle":181,"officialTitle":182,"acronym":4,"eligibilityCriteria":183,"healthyVolunteers":11,"sex":16,"minAge":184,"maxAge":185,"enrollmentInfo":186,"targetDuration":4,"studyType":22,"phases":188,"briefSummary":189,"conditions":190,"keywords":4,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":195,"lastUpdatePostDateStruct":196,"startDateStruct":198,"completionDateStruct":200,"leadSponsor":202,"locationsCount":50},"100539372","atomized-inhalation-icg-for-treatment-of-congenital-lung-malformations-100539372","NCT06302985","Atomized Inhalation ICG for Treatment of Congenital Lung Malformations","Application of Atomized Inhalation ICG in Thoracoscopic Surgery for Pulmonary Sequestration in Children: a Multicentre Prospective Study","Inclusion Criteria:\n\n* children with congenital lung malformations diagnosed by CT or MRI scan\n\nExclusion Criteria:\n\n* 1\\. ages \\\u003C3 months and \\>14 years 2. complicated other life-threatening disease; 3. complicated severely pulmonary infection","3 Months","14 Years",{"count":187,"type":21},50,[24],"To investigate the safety and effectiveness of preoperative aerosol inhalation ICG solution for thoracoscopic accurate resection of congenital lung malformations in children.",[191,192,193,29,194],"Pulmonary Sequestration","Congenital Pulmonary Airway Malformation","Indocyanine Green","Children","2024-10-13",{"date":197,"type":42},"2024-10-16",{"date":199,"type":42},"2024-03-01",{"date":201,"type":21},"2050-12-31",{"name":203,"class":49},"Jiexiong Feng"]